170 related articles for article (PubMed ID: 8971830)
1. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).
Penn RD; Kroin JS; York MM; Cedarbaum JM
Neurosurgery; 1997 Jan; 40(1):94-9; discussion 99-100. PubMed ID: 8971830
[TBL] [Abstract][Full Text] [Related]
2. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group.
Neurology; 1996 May; 46(5):1244-9. PubMed ID: 8628460
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.
Miller RG; Petajan JH; Bryan WW; Armon C; Barohn RJ; Goodpasture JC; Hoagland RJ; Parry GJ; Ross MA; Stromatt SC
Ann Neurol; 1996 Feb; 39(2):256-60. PubMed ID: 8967757
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.
Aebischer P; Schluep M; Déglon N; Joseph JM; Hirt L; Heyd B; Goddard M; Hammang JP; Zurn AD; Kato AC; Regli F; Baetge EE
Nat Med; 1996 Jun; 2(6):696-9. PubMed ID: 8640564
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: relation to parameters of the acute-phase response. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
Clin Neuropharmacol; 1995 Dec; 18(6):500-14. PubMed ID: 8681311
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
Clin Neuropharmacol; 1995 Dec; 18(6):515-32. PubMed ID: 8681312
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis.
Miller RG; Bryan WW; Dietz MA; Munsat TL; Petajan JH; Smith SA; Goodpasture JC
Neurology; 1996 Nov; 47(5):1329-31. PubMed ID: 8909453
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.
Ochs G; Penn RD; York M; Giess R; Beck M; Tonn J; Haigh J; Malta E; Traub M; Sendtner M; Toyka KV
Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Jun; 1(3):201-6. PubMed ID: 11464953
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Pharmacodynamics of Intrathecal Injection of Recombinant Human HGF (KP-100) in Subjects With Amyotrophic Lateral Sclerosis: A Phase I Trial.
Warita H; Kato M; Asada R; Yamashita A; Hayata D; Adachi K; Aoki M
J Clin Pharmacol; 2019 May; 59(5):677-687. PubMed ID: 30536581
[TBL] [Abstract][Full Text] [Related]
10. Ciliary neurotrophic factor fused to a protein transduction domain retains full neuroprotective activity in the absence of cytokine-like side effects.
Rezende AC; Peroni D; Vieira AS; Rogerio F; Talaisys RL; Costa FT; Langone F; Skaper SD; Negro A
J Neurochem; 2009 Jun; 109(6):1680-90. PubMed ID: 19457136
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic benefit of ciliary neurotrophic factor in progressive motor neuronopathy depends on the route of delivery.
Haase G; Pettmann B; Bordet T; Villa P; Vigne E; Schmalbruch H; Kahn A
Ann Neurol; 1999 Mar; 45(3):296-304. PubMed ID: 10072043
[TBL] [Abstract][Full Text] [Related]
12. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease.
Bongioanni P; Reali C; Sogos V
Cochrane Database Syst Rev; 2004; 2004(3):CD004302. PubMed ID: 15266526
[TBL] [Abstract][Full Text] [Related]
13. Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat.
Dittrich F; Thoenen H; Sendtner M
Ann Neurol; 1994 Feb; 35(2):151-63. PubMed ID: 8109896
[TBL] [Abstract][Full Text] [Related]
14. Ciliary neurotrophic factor infused intracerebroventricularly shows reduced catabolic effects when linked to the TAT protein transduction domain.
Vieira AS; Rezende AC; Grigoletto J; Rogério F; Velloso LA; Skaper SD; Negro A; Langone F
J Neurochem; 2009 Sep; 110(5):1557-66. PubMed ID: 19573019
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells.
Zurn AD; Henry H; Schluep M; Aubert V; Winkel L; Eilers B; Bachmann C; Aebischer P
Cell Transplant; 2000; 9(4):471-84. PubMed ID: 11038064
[TBL] [Abstract][Full Text] [Related]
16. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Miller TM; Pestronk A; David W; Rothstein J; Simpson E; Appel SH; Andres PL; Mahoney K; Allred P; Alexander K; Ostrow LW; Schoenfeld D; Macklin EA; Norris DA; Manousakis G; Crisp M; Smith R; Bennett CF; Bishop KM; Cudkowicz ME
Lancet Neurol; 2013 May; 12(5):435-42. PubMed ID: 23541756
[TBL] [Abstract][Full Text] [Related]
17. The distribution of medication along the spinal canal after chronic intrathecal administration.
Kroin JS; Ali A; York M; Penn RD
Neurosurgery; 1993 Aug; 33(2):226-30; discussion 230. PubMed ID: 7690122
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF.
Aebischer P; Pochon NA; Heyd B; Deglon N; Joseph JM; Zurn AD; Baetge EE; Hammang JP; Goddard M; Lysaght M; Kaplan F; Kato AC; Schluep M; Hirt L; Regli F; Porchet F; De Tribolet N
Hum Gene Ther; 1996 May; 7(7):851-60. PubMed ID: 8860837
[TBL] [Abstract][Full Text] [Related]
19. Ciliary neurotrophic factor inhibits brain and peripheral tumor necrosis factor production and, when coadministered with its soluble receptor, protects mice from lipopolysaccharide toxicity.
Benigni F; Villa P; Demitri MT; Sacco S; Sipe JD; Lagunowich L; Panayotatos N; Ghezzi P
Mol Med; 1995 Jul; 1(5):568-75. PubMed ID: 8529123
[TBL] [Abstract][Full Text] [Related]
20. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse.
Sagot Y; Tan SA; Baetge E; Schmalbruch H; Kato AC; Aebischer P
Eur J Neurosci; 1995 Jun; 7(6):1313-22. PubMed ID: 7582105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
